Our sister project, Amyloid imaging to prevent Alzheimer’s disease (AMYPAD), which began its activities on October 2016, has recently enrolled its first research participant.
The first participant was recruited in Geneva, Switzerland, within the diagnostic and patient management sub-study (DMPS) of the AMYPAD project. In this clinical study, researchers aim to include subjects suspected of possible Alzheimer’s disease and determine the usefulness of β-amyloid imaging as a diagnostic marker for Alzheimer’s disease. The study will involve people with dementia, but also subjects with mild cognitive impairment (MCI) or subjective cognitive decline (SCD), and will study the impact of β-amyloid PET on both diagnostic confidence, patient management and resource utilization.
For further information, visit www.amypad.eu or please contact: email@example.com
The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.